Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04686305
Ignite Creation Date: 2024-05-06 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 1:52 PM
Study NCT ID: NCT04686305
Protocol Section: NCT04686305
Start Identification Module Data
Expand Identification Module Data
Brief Title: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2 Non-squamous NSCLC
Official Title: A Phase Ib Multicenter Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan T-DXd and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer NSCLC and Human Epidermal Growth Factor Receptor 2 HER2 Overexpression OE DESTINY-Lung03
Acronym: DL03
Organization: AstraZeneca
Organization Class: INDUSTRY
Organization Study ID: D967YC00001
Secondary IDs
Secondary ID Type Domain Link
2020-003260-31 EUDRACT_NUMBER None None
Start Status Module Data
Status Verified Date: 2024-10
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: AstraZeneca
Lead Sponsor Class: INDUSTRY
Lead Sponsor: AstraZeneca
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload